Last updated: May 16, 2026
HYPAQUE SODIUM 20% clinical trials update, market analysis, and exclusivity timeline
Executive summary: HYPAQUE SODIUM 20% (iopamidol 20% w/v oral/IV contrast products under the brand “Hypaque”) is a legacy iodinated contrast agent. Public clinical-trials activity is limited and largely redundant with ongoing post-marketing safety and manufacturing-quality programs rather than new phase development. Commercially, the product sits in a mature, price-competitive iodinated contrast market where market share is driven by tender contracts, pack formats, supply reliability, and formulary positioning. Near-term revenue projection is more sensitive to generic and alternative-brand substitution and utilization trends (CT and interventional volumes) than to new clinical differentiation.
What is HYPAQUE SODIUM 20% (iopamidol) and how is it used clinically?
Short answer: HYPAQUE SODIUM 20% is an iodinated contrast formulation containing iopamidol used to enhance imaging contrast in radiology. The “20%” strength refers to iodine concentration delivered in the product’s administered volume, with exact labeling and route depending on the specific commercial pack and jurisdiction.
Route, dosing strength, and imaging context
- Strength: 20% (w/v), iodine delivery optimized for specific imaging protocols.
- Clinical use context (typical iodinated contrast roles):
- Computed tomography (CT) contrast enhancement
- Contrast-enhanced radiography in selected indications
- Interventional radiology procedural imaging support
Key safety and operational considerations (what impacts uptake)
- Renal safety monitoring and hydration protocols influence prescribing practices.
- Allergy/hypersensitivity risk and premedication protocols affect operational workflows.
- Contrast volume and osmolarity preferences influence selection versus alternative agents.
What clinical trials are underway or recently completed for HYPAQUE SODIUM 20%?
Short answer: For HYPAQUE SODIUM 20% specifically, public trial signals are thin. The brand is an established contrast agent, so most “updates” in public registries relate to:
- Post-marketing observational studies
- Pharmacovigilance registries
- Nonclinical/CMC bridging tied to manufacturing changes
- Comparator or protocol studies that evaluate iodinated contrast performance broadly (often not branded)
Typical trial pattern for legacy iodinated contrast agents
- Registry listings skew toward:
- Safety surveillance (adverse event characterization)
- Imaging quality scoring in routine practice
- Comparative use under standard protocols
What to look for in the trial record (practical screens)
- Whether endpoints are:
- Adverse event rates (nephropathy, hypersensitivity)
- Imaging quality metrics (enhancement, artifact scoring)
- Protocol outcomes (procedure success, turnaround time)
- Whether the study is:
- Brand-specific (HYPAQUE SODIUM 20%)
- Ingredient-class based (iopamidol broadly)
- Cross-contrast comparisons (iopamidol vs iohexol, ioversol, iopromide, etc.)
Clinical-trials update deliverable (what is determinative for business decisions)
For a legacy contrast brand, the decisive “trial update” for market impact is rarely efficacy novelty. It is:
- New safety signals that force label changes
- Evidence that shifts imaging protocol preference
- Supply disruptions tied to manufacturing changes that trigger FDA or regulator actions
- New commercialization rights that affect procurement
What does the FDA label and approval history imply for HYPAQUE SODIUM 20% commercialization?
Short answer: FDA approvals for legacy iodinated contrast agents generally fall under original NDA approvals with periodic updates to:
- Safety language and warning sections
- Dosing and contraindication refinements
- Manufacturing changes via supplements
What label changes typically do to demand
- Renal-risk guidance can shift utilization patterns to alternative agents in high-risk cohorts.
- Hypersensitivity premedication language impacts pharmacy and radiology workflows.
- Concentration-specific protocols determine which strength dominates use in CT vs other modalities.
How this affects market projection
Market projection is driven by:
- CT volume and interventional procedure counts
- Mix of high-risk patient populations (diabetes, CKD)
- Substitution elasticity to lower-cost equivalents
What is the Orange Book status of HYPAQUE SODIUM 20% and how many patents cover it?
Short answer: An Orange Book and patent-count analysis requires the specific approved application and listed active ingredient/product code for the exact “HYPAQUE SODIUM 20%” presentation and manufacturer. Without that mapping, the patent estate cannot be quantified accurately.
When does HYPAQUE SODIUM 20% lose exclusivity (and what does that mean for generic entry risk)?
Short answer: Exclusivity and generic-entry risk for legacy iodinated contrasts are typically dominated by:
- Whether there are still listed patents in the Orange Book for the specific product presentation
- Whether the market is already serviced by approved AB-rated generics or alternative-brand equivalents
- Whether reformulations or device/packaging changes create incremental IP
A precise exclusivity or expiration timeline requires the exact FDA application and listed patent numbers for the product presentation.
Which companies compete with HYPAQUE SODIUM 20% in iodinated contrast CT markets?
Short answer: Iodinated contrast competition is concentrated among major contrast manufacturers and their branded/generic portfolios, with substitution by:
- formulary status,
- contract pricing,
- supply reliability,
- and perceived tolerability in institutional protocols.
Competitive set (ingredient-class rivals)
Common iodinated contrast active ingredients used in the US and EU include:
- Iohexol
- Ioversol
- Iopromide
- Iodixanol (often an alternative osmolarity class)
- Diatrizoate class (different dosing practices)
What drives actual share shifts
- Multi-year procurement contracts
- Group purchasing organization (GPO) formularies
- Hospital-specific safety pathways and premed protocols
- Radiology preference patterns for specific contrast classes
What patent litigation affects iopamidol/iodinated contrast products and brand survival?
Short answer: For legacy contrast agents, the most market-relevant legal activity is usually:
- Patent listings and enforcement tied to specific presentations, concentrations, or manufacturing processes
- Paragraph IV challenges are more typical when there is still meaningful listed IP
- Settlements can preserve some exclusivity windows for specific presentations, but impacts depend on the exact FDA application
A litigation-risk inventory for HYPAQUE SODIUM 20% requires the product’s specific Orange Book listing and any case docket tied to that presentation.
What formulations are protected for HYPAQUE SODIUM 20% (concentration, route, packaging)?
Short answer: For contrast agents, formulation IP can include:
- Concentration-specific compositions
- Stabilizers and excipients
- Manufacturing process controls and impurity specifications
- Packaging and delivery attributes where patented
Quantifying which formulations are protected depends on the exact patent list linked to the specific HYPAQUE SODIUM 20% NDA/BLA/app.
Clinical and regulatory risk: does iopamidol 20% have biosimilar risk or biologics-like competition?
Short answer: No. HYPAQUE SODIUM 20% is a small-molecule iodinated contrast agent, not a biologic. Biosimilar pathways do not apply; competition is from generics and alternative branded small-molecule contrast products.
Market size and demand drivers for iodinated contrast media: what matters for HYPAQUE SODIUM 20%?
Short answer: Demand growth for iodinated contrast is primarily linked to imaging volume and procedure mix, while brand-level share depends on contract and substitution dynamics.
Core demand drivers
- CT utilization growth in routine and emergency settings
- Interventional radiology volume expansion
- Patient mix shift toward more comorbid imaging patients, changing protocol selection
- Hospital budget pressure driving cost-optimized substitution
Core supply and commercial drivers
- Manufacturing capacity and batch release reliability
- Shelf-life constraints and procurement lead times
- Regulatory inspection outcomes affecting sourcing continuity
Market analysis and pricing: how do legacy brands like HYPAQUE SODIUM 20% usually perform?
Short answer: Legacy iodinated contrast brands often face:
- price erosion after generic equivalents or alternative brands gain formulary positions,
- limited ability to command premium absent clear protocol superiority,
- revenue resilience if embedded in established institutional pathways.
Business levers that typically outperform “new clinical claims”
- Contract positioning for high-use concentrations and pack sizes
- Pharmacist and radiology guideline alignment
- Supply assurance and fulfillment reliability
- Tender participation with pricing stability
Revenue projection for HYPAQUE SODIUM 20%: base case, bull case, bear case
Short answer: A numeric projection cannot be produced from the information provided because HYPAQUE SODIUM 20% requires specific financial baselines (brand revenue, channel mix, geography, and pack-level volume) and registry data (exact FDA listing for the product presentation). Without those anchors, any quantified forecast would be non-actionable.
Key takeaways
- HYPAQUE SODIUM 20% is a mature iodinated contrast product; public clinical-trials activity is typically limited to protocol or safety/observational studies rather than brand-changing Phase 3 programs.
- Market performance is shaped by CT and interventional volumes plus substitution dynamics driven by hospital formularies and procurement pricing.
- The most business-relevant exclusivity, patent, litigation, and Orange Book status assessments cannot be completed without tying “HYPAQUE SODIUM 20%” to its exact FDA application/presentation and listed patent numbers.
FAQs
- Is HYPAQUE SODIUM 20% the same as iopamidol 20% in the regulatory sense?
- Which iodinated contrast agents are most substitutable for iopamidol in hospital formularies?
- Do adverse renal or hypersensitivity outcomes materially change contrast procurement decisions?
- How do packaging and concentration differences affect tender selection for iodinated contrast?
- What regulatory signals typically cause abrupt shifts away from a specific contrast brand?
References
- (No sources cited; request did not provide product-specific FDA/Orange Book or trial registry identifiers.)
